Kyle Munz

Real-word and subgroup analyses in spinal muscular atrophy (SMA) provide great reference data for long-term comparison. This approach can lead to valuable findings that better assess patterns throughout the various SMA types, rather than tracking average changes throughout entire cohorts. […]

The Biden administration has put forth a proposal to revise various Medicare and Medicaid regulations and include obesity medications as part of their coverage. This move marks perhaps one of the final health policy initiatives of Biden’s presidency. The new

Yesterday, Marks Shorla Oncology’s announced the FDA’s approval of imatinib (Imkeldi). With this decision, the agent becomes the first oral, liquid tyrosine kinase inhibitor (TKI) indicated for the treatment of various cancers including gastrointestinal tumors (GIST), myelodysplastic syndromes (MDS), or

The American Heart Association’s (AHA) centennial event brought together a plethora of diverse perspectives spanning the field of cardiology, nephrology, radiology, and more. Scientific and educational sessions alike at this year’s meeting underscored the transformative potential of multidisciplinary collaboration, holistic

The FDA approved mavacamten (Camzyos), a cardiac myosin inhibitor, for the treatment of adult patients with New York Heart Association class II to III obstructive hypertrophic cardiomyopathy (HCM) in 2022. Milind Desai, MD, MBA, Cleveland Clinic, reported on the drug’s

Heart failure remains a serious complication, contributing to great rates of morbidity and mortality in affected patients. Persistent disparities in heart failure have reinforced the need to take a closer look at why some populations bear the brunt of disease

Developments in atherosclerosis were among the many novel points of progress highlighted at this year’s American Heart Association (AHA) conference. As the latest research sheds light on the new pathways, therapeutic possibilities, and mechanisms associated with vascular disease, Masanori Aikawa,

Women carry more risk for heart failure with preserved ejection fraction (HFpEF); however, female representation in clinical trials for heart failure remains overwhelming insufficient. New data from the FINEARTS-HF trial, which evaluated the safety and efficacy of finerenone (Kerendia), offers

The time has for cardiovascular medicine to form its very own certifying board. As the American Board of Medical Specialties (ABMS) weighs over submitting a formal application, the creation of an American Board of Cardiovascular Medicine (ABCVM) has the potential